Categories
Culture Education Local News

Top NJ public health school students and faculty partner with state initiative to address Black maternal and infant mortality crisis

EWING, N.J.  Students and faculty in the School of Nursing, Health, and Exercise Science (SNHES) at The College of New Jersey (TCNJ) are partnering with Nurture NJ to tackle the state’s Black maternal and infant mortality crisis. First Lady of New Jersey, Tammy Murphy, officially launched Nurture NJ in early 2019 as a statewide initiative committed to equity in maternal and infant health outcomes for women of color. New Jersey’s mortality rates among Black, non-Hispanic women are nearly seven times greater than those of non-Hispanic white women–more than double the national average.

 

To address this crisis, TCNJ’s public health department will offer a course for aspiring doulas–helpers employed to support women giving birth–to expand advocacy for at-risk mothers and newborns throughout the state. Launching in summer 2022, the program will train students on the NJ Family Care doula registration process and Nurture NJ recommendations for succeeding in this field. Sonali Golpakrishnan, a TCNJ graduate student involved in developing the class, remarks, “Community-based doulas provide non-medical and emotional support, ensuring that mothers’ needs are heard before, during, and after birth. Doula involvement has shown to improve birth outcomes for mothers and babies.”

 

One professor spearheading this program, Ria Rodney, explains the importance of this track to strengthening equity in NJ: “Doulas are a lifeline in keeping families safe both at home and in the hospital… By offering a doula course, students will get hands-on healthcare experience very early in their liberal learning education, and be encouraged to provide an essential need to the community.”

 

Students and faculty from TCNJ’s public health department were first asked by the Nurture NJ to assist with the 2020 Black Maternal and Infant Health Leadership Summit. Assistant Professor of Public Health and co-developer of the new doula track, Dr. Natasha Patterson, describes the college’s role at this conference: “At the summit, students and faculty served as facilitators and note-takers. We were trained and provided with a draft of the Nurture NJ Strategic Plan, including a section for academic institutions outlining the role we can play to help address the devastating Black maternal and infant mortality rate in New Jersey.”

 

A public health student who volunteered at the summit, Salomine Ekambi, Class of 2022, adds, “This summit is essential for improving equity because it raises awareness of the experiences endured by women of color. It’s a call for action…This work has enabled me to witness how different agencies and health systems interact to achieve a common goal.”

 

TCNJ’s School of Nursing, Health, and Exercise Science’s Dean Carole Kenner explains, “The school’s partnership with statewide initiatives to combat tragic maternal healthcare disparities empowers students to think critically beyond the classroom. Our faculty act as true mentors to students, involving them in efforts critical to achieving a more equitable society. This is what makes our public health program stand out.” TCNJ’s SNHES is the number two public health schoolin New Jersey.

 

TCNJ’s School of Nursing, Health, and Exercise Science educates aspiring health professionals to become future leaders across the healthcare industry. Faculty work closely with local healthcare partners to provide students with applicative skills and foundational knowledge. The nationally acclaimed school is dedicated to preparing individuals—through programs in nursing, public health, exercise science, and physical education teaching—for the many rewards of guiding people, communities, and populations toward improved health outcomes.

 

Contact Information

Crothers Consulting | info@crothersconsulting.co | (800) 831-3840

Categories
Culture Local News

County Clerk holds annual drive to benefit local charities

TRENTON, N.J. — Following their annual holiday drive benefiting local charities, Mercer County Clerk Paula Sollami Covello and her staff delivered a large amount of donations to both the Children’s Home Society of New Jersey and EASEL (Ewing Animal Rescue League).

Mercer County Clerk Paula Sollami Covello with Deputy County Clerk Walker Worthy Jr. at EASEL
— Courtesy photo

 

This year, the County Clerk and her staff along with the County Courthouse staff and Trenton Fire Director Kenneth Douglas all assisted in collecting toys and clothing to benefit the Children’s Home Society. The Clerk’s Office also collects pet food and pet supplies and monetary donations for local animal shelters.

 

“If the public puts their trust in you to serve them, your service should extend beyond your official title,” said Sollami Covello.

 

“Of course, this would not be possible without those generous souls and businesses who donated to help our local charities. By collecting toys, clothing, pet food and money, we hope to the make the holidays brighter for the children and animals in need.”

 

The Children’s Home Society offers many services to vulnerable families including women’s health services, clinical and behavioral counseling, educational opportunities and more.

 

For more information about how to donate or get involved, visit their website at https://www.chsofnj.org/ or call 609-695-6274.

 

Both EASEL and the Trenton Animal Shelter are committed to reducing the euthanizing of homeless animals in Mercer County. They are also accepting donations and volunteers.

 

For more information, visit EASEL’s website at https://www.easelnj.org/ or call the Trenton Animal Shelter at 609-989-3254.

Categories
Culture Local News

Most Mercer County offices to close for Martin Luther King Jr. Day

TRENTON,  N.J. — Most Mercer County government offices will be closed Monday, Jan. 17, 2022, in observance of Martin Luther King Jr. Day.

 

The Ewing, Hickory Corner, Lawrence and West Windsor branches of the Mercer County Library System will be open for holiday curbside hours, 10 a.m. to 4:30 p.m. All other branches will be closed.

 

The following County offices and facilities will remain open: Trenton-Mercer Airport (except for administrative offices), Correction Center, Sheriff’s Office and the Emergency Services Communication Center.

 

Mercer County Park Commission facilities will have the following hours on Jan. 17:

 

Ice Skating Center, 10 a.m. to 3 p.m.;

 

Tennis Center, 7:30 a.m. to 10:30 p.m.;

 

Mercer Oaks East and Princeton Country Club golf courses, 8 a.m. to 4 p.m., weather permitting.

 

Wildlife Center, 10 a.m. to 3 p.m. by appointment only.

 

Howell Living History Farm, Mercer County Stables, Tulpehaking Nature Center and Park Commission administrative offices will be closed on Jan. 17.

 

Mercer Oaks West and Mountain View golf courses are closed during January.

 

For more information on Park Commission facilities, visit www.mercercountyparks.org.

Categories
Local News Science

The McQuade Center for Strategic Research and Development and Mindset Pharma collaborate to develop psychedelic medicines

PRINCETON, N.J. — (BUSINESS WIRE) — The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) today announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs.

“Exploring multiple paths is essential as we work to address the unique needs of individuals living with mental health conditions,” said Robert McQuade, Ph.D., president, McQuade Center for Strategic Research and Development, LLC, and chief strategic officer, Otsuka Pharmaceutical Development & Commercialization, Inc. “We look forward to collaborating with Mindset on these assets and are hopeful that medical psychedelics could be approved to treat mental illness in the future.”

 

MSRD, which identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders, will financially and operationally support the development of two families of Mindset’s novel medical psychedelic compounds through Phase 1a and Phase 1b clinical trials. MSRD has made an upfront cash payment of $5 million USD to Mindset and under the terms of the agreement, MSRD and Mindset may agree to expand the collaboration to continue to develop the compounds as pharmaceutical products.

 

In addition, Mindset has granted MSRD a right of first refusal with respect to any asset sale, exclusive licensing or collaboration opportunities pertaining to the drugs and a right of first negotiation with respect to a merger, acquisition or asset sale related to Mindset, both in exchange for the upfront payment, further collaboration, and funding of the development of Mindset’s novel compounds. MSRD also has the ability to potentially receive single-digit percentage royalty payments under certain circumstances when the right of first refusal is not consummated or the agreement is terminated.

 

“It is our great pleasure to collaborate with MSRD, a member company of Otsuka, to further the development of two of our families of novel psychedelic compounds. We look forward to leveraging their extensive experience in drug development and CNS indications to accelerate and de-risk our development pathway as we prepare to launch clinical trials,” said James Lanthier, chief executive officer of Mindset. “There is a high unmet need for innovative treatments of mental illness. This collaboration further validates our belief that optimized and patentable next-generation psychedelic compounds will be the future of treatments for mental illness.”

 

Mr. Richard Patricio, chairman of Mindset’s board, added, “This transformational transaction is a validation of what our team has accomplished over the last several years. We are ecstatic that Otsuka has chosen to collaborate with Mindset in the novel psychedelic drug development space and see this as a pivotal moment in Mindset’s maturation. Our team is excited to work closely with MSRD to help meet the unmet needs of millions of people worldwide suffering with a variety of mental disorders. The future is truly exciting.”

 

About Mindset Pharma

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds. For further information on Mindset, please visit our website at www.mindsetpharma.com.

 

About the McQuade Center for Strategic Research and Development (MSRD)

Established in 2019, by the Otsuka pharmaceutical business in the U.S., the mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products.

 

Otsuka is dedicated to investing in innovative and creative products in areas of unmet need and MSRD was created as an extension of this commitment to support and identify early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders. For more information, please visit https://msrd-us.com/.

 

About Otsuka

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.

 

In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

 

Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology, and cardiology, using cutting-edge technology to address unmet healthcare needs.

 

OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13.3 billion in 2020.

 

All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.

Contacts

For Mindset Pharma:

Investor Contact:
Allison Soss/Tim Regan

KCSA Strategic Communications

Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Media Contact:
McKenna Miller

KCSA Strategic Communications

Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:

James Lanthier, CEO

Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development

Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Media contacts for Otsuka:

Otsuka in U.S.

Jill Roman

Corporate Communications

Otsuka America Pharmaceutical, Inc.

jill.roman@otsuka-us.com
+1 215 595 8424

Otsuka outside U.S.

Jeffrey Gilbert

Leader, Pharmaceutical PR

Otsuka Pharmaceutical, Co., Ltd.

gilbert.jeffrey@otsuka.co.jp
+81 3 6717 1410

Categories
Business Local News

Rocket Pharmaceuticals to present at the 40th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J. — (BUSINESS WIRE) — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com/. The webcast replay will be available on the Rocket website following the conference.

 

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

 

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2022 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, Rocket’s plans for the advancement of its Danon Disease program following the lifting of the FDA’s clinical hold and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2020, filed March 1, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media

Kevin Giordano

Director, Corporate Communications

kgiordano@rocketpharma.com

Investors

Mayur Kasetty, M.D., M.B.A.

Director, Business Development & Operations

investors@rocketpharma.com

Categories
Environment Local News

Park Commission to implement Community Based Deer Management

HOPEWELL TOWNSHIP, N.J. — The Mercer County Park Commission has been approved for a Community Based Deer management permit from the New Jersey Division of Fish and Wildlife. The Community Based Deer Management (CBDM) permit allows for additional opportunities to improve forest understory and the overall ecological condition of natural areas through deer reductions beyond standard state hunting regulations.  Reducing deer overpopulation also improves public safety by reducing deer-vehicle collisions.

 

The additional measures permitted in the CBDM program will allow a professional culling firm to perform management activities during an extended season through March 31, 2022, at Baldpate Mountain and select regions of Mercer Meadows in Hopewell Township.  Management activities approved in the Park Commission’s permit include: Deer harvest by crossbow and firearm, culling during evening hours, and periodic closures for culling outside of the traditional State hunting season through March 31.

 

At Mercer Meadows, only the Curlis Woods region and the Ecological District are included in the permit. Beginning in January, these areas will allow for bow culling 7 days a week, through 9 p.m. each day until March 31. These regions will remain open to the public during this period. Park users are advised to remain on trails and wear bright colored clothing. All culling activity will take place from an elevated tree stand and a 75-foot safety buffer is in place on either side of all County-recognized trails.

 

The Curlis Woods region will BE CLOSED to the public for shotgun culling on:

  • Wednesday, January 19 through Friday, January 21
  • Wednesday, January 26 through Friday, January 28
  • Thursday, March 3 through Friday, March 4
  • Thursday, March 10 through Friday, March 11
  • Saturday, March 5 and 12, from sunset to 9 p.m.

 

At Baldpate Mountain, including Belle Mountain and Fiddler’s Creek Preserve, the permit allows for extended evening culling (sunset through 9 p.m.)  February 1 through February 18, when the state hunting season ends. Beginning on Monday, February 21, bow culling may take place Monday through Friday, from sunrise to 9 p.m. until March 31. Shotgun culling may take place beginning on Monday, February 21 through March 31, 7 days a week from sunset to 9 p.m. when the park is closed to the public.

 

Baldpate Mountain, Belle Mountain and Fiddler’s Creek Preserve will BE CLOSED to the public for shotgun culling on:

 

  • Thursday, March 17 through Friday, March 18
  • Thursday, March 24 through Friday, March 25
  • Saturday, March 19 and 26, from sunset to 9 p.m.

 

The above dates do not include closures as part of the Park Commission’s existing deer management program. The deer management program complies with all of the hunting regulations set by the State; in addition, the Park Commission has adopted County rules for the program. All hunting must be done from an elevated tree stand; hunters are not permitted to hunt from the ground. There is no shooting across park trails. Please visit www.mercercountyparks.org for details on all closures for deer management.

Categories
Business Local News

Church and Dwight completes purchase of TheraBreath®

EWING, N.J. — (BUSINESS WIRE) — Church & Dwight Co., Inc. (NYSE:CHD) has completed its previously announced acquisition of TheraBreath®, the #2 brand in the alcohol-free mouthwash category in the United States.

 

The transaction was completed under the original terms announced on November 29, 2021, which called for Church & Dwight to pay $580 million in cash at closing.

 

“Oral care is important to us strategically,” said Matthew T. Farrell, Church & Dwight Chief Executive Officer. “TheraBreath® will be the Company’s 14th power brand and represents a powerful addition to our existing oral care portfolio which includes ARM & HAMMER® toothpaste, SPINBRUSH® battery-operated toothbrushes, ORAJEL® oral analgesics and WATERPIK® water flossers. The TheraBreath® brand is a problem/solution product and one of the fastest growing brands in the mouthwash category. This acquisition gives Church and Dwight a strong position in a growing category with tailwinds as the brand skews towards younger consumers and consistently has a high level of brand loyalty and repeat purchase.”

 

Church & Dwight Co., Inc., founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household and specialty products under recognized brand names such as ARM & HAMMER®, TROJAN®, OXICLEAN®, SPINBRUSH®, FIRST RESPONSE®, NAIR®, ORAJEL®, XTRA®, L’IL CRITTERS® and VITAFUSION®, BATISTE®, WATERPIK®, ZICAM®, FLAWLESS® and THERABREATH®. These 14 key brands represent approximately 85% of the Company’s product sales. For more information, visit the Company’s website.

Contacts

Rick Dierker

Chief Financial Officer

609-806-1900

Categories
Business Local News

Billtrust to participate in Needham’s 24th Annual Virtual Growth Conference

LAWRENCEVILLE, N.J. — (BUSINESS WIRE) — BTRS Holdings Inc. (“Billtrust” or “the Company”) (NASDAQ: BTRS), a B2B accounts receivable automation and integrated payments leader, today announced that members of the Company’s management team will be participating in Needham’s 24th Annual Virtual Growth Conference on Monday, January 10th, 2022 at 3:30 pm ET.

 

Live webcasts and replay of the presentation will be available on the Company’s investor relations website at https://www.billtrust.com/about/investors.

 

About BTRS Holdings

Billtrust (NASDAQ: BTRS) is a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce. Accounts receivable is broken and relies on conventional processes that are outdated, inefficient, manual and largely paper based. Billtrust is at the forefront of the digital transformation of AR, providing mission-critical solutions that span credit decisioning and monitoring, online ordering, invoice delivery, payments and remittance capture, invoicing, cash application and collections.

 

For more information, visit Billtrust.com.

Contacts

Investor Contact:

John T. Williams

IR@billtrust.com

Media Contact:

Paul Accardo

paccardo@billtrust.com

Categories
Culture Local News

Most Mercer County government offices to close for Christmas and New Year’s holidays

TRENTON, N.J. — Most Mercer County government offices and facilities will be closed Friday, Dec. 24, 2021, in observance of Christmas, and Friday, Dec. 31, 2021, for New Year’s observance.

 

The Mercer County Clerk’s Office in Trenton and the County Connection office in Hamilton will be closed on both Dec. 24 and 31. The Clerk’s Office will not have extended evening office hours on Wednesday, Dec. 29 but will close at 4:30 p.m. that day. All branches of the Mercer County Library System will be closed on Dec. 24, 25 and 31, and Jan. 1.

 

The following County offices and facilities will remain open: Trenton-Mercer Airport (except for administrative offices), Correction Center, Sheriff’s Office and the Emergency Services Communication Center.

 

Please remember that when visiting Mercer County government buildings and other indoor facilities, face masks must be worn regardless of one’s vaccination status.

 

Mercer County Park Commission facilities will have the following holiday hours: the Tennis Center will be closed Dec. 25 but will be open Dec. 24 from 7:30 a.m. to noon, Dec. 31 from 7:30 a.m. to 6 p.m. and Jan. 1 from 7:30 a.m. to 9 p.m. The Skating Center will be closed Dec. 25 but will have public sessions Dec. 24 from 10 a.m. to 2 p.m., Dec. 31 from 10 a.m. to noon and 1 to 3 p.m., and Jan. 1 from 10 a.m. to noon, 1 to 3:30 p.m., 5 to 7 p.m. and 7:45 to 9:45 p.m. All four county golf courses will be closed Dec. 25 but will be open Dec. 24 and 31, and Jan. 1 from 8 a.m. to 2 p.m. Mercer County Stables will be closed Dec. 25 and Jan. 1 but will be open Dec. 24 and 31 from 7 a.m. to 3 p.m. The Wildlife Center will be open Dec. 24, 25 and 31, and Jan. 1 by appointment only. Howell Living History Farm(including picnic area and parking lot) is closed to the public until the new program year begins Saturday, Jan. 29, 2022. The Friends of Howell Farm Gift Shop, located at the farm’s Visitor Center, is open from 10 a.m. to 4 p.m., Tuesday-Thursday, through Dec. 23. The Tulpehaking Nature Center is currently closed to the public. Park Commission administrative offices will be closed Dec. 24 and 31.

 

For more information on Park Commission facilities, visit www.mercercountyparks.org.

Categories
Education Local News

Leading N.J. exercise science program provides students with hands-on research opportunities at Human Performance Lab

EWING, N.J. — Students in the School of Nursing, Health, and Exercise Science (SNHES) at The College of New Jersey (TCNJ) are getting hands-on experience researching physical fitness best practices at the school’s Human Performance Lab.

 

“Currently, we are examining the effects of different warm-up protocols on maximal aerobic power in children (8-12 years old). In short, a warm-up is an important component of any exercise session or sport competition because the design can confer numerous benefits and enhance performance,” says Professor of Exercise Science Dr. Avery Faigenbaum. “As a majority of our students go on to graduate schools, their participation in research can also benefit their future academic pursuits.”

Students in the School of Nursing, Health, and Exercise Science (SNHES) at The College of New Jersey (TCNJ) are getting hands-on experience researching physical fitness best practices at the school’s Human Performance Lab.

 

TheCenters for Disease Control(CDC) recommends children ages 6 to 17 years old have at least 60 minutes of physical activity on a daily basis.

 

A student working on this project, Caitlyn Finnerty, Class of 2022, says, “…we are in the process of assembling our motion analysis system that is commonly used for biomechanics research. This system is a great tool that we use to assess any mechanical advantages or discrepancies in the body when performing exercises …Understanding the importance of exercise science research is crucial, but performing the research techniques as undergraduate students enables us to be more equipped and qualified for greater health conversations.”

 

Describing the benefits of the Human Performance Lab for students, Professor of Exercise Science Dr. Jie Kang explains, “Students assist faculty-led research in many ways, including screening subjects, calibrating equipment, supervising the warm-up protocol, operating VO2max tests and performing data analysis. These research skills are essential for conducting human subject experimentation. By participating in research in the Human Performance Lab, students gain the necessary experience that will help them get into graduate schools and lead successful careers.”

 

Founded in 2000, the Human Performance Lab has been a setting for numerous successful studies on physiology, fitness routines and exercise best practices.

 

TCNJ’s School of Nursing, Health, and Exercise Science Dean Carole Kenner remarks, “The Human Performance Lab is unique to our school and offers students tangible experiences for real world application. This is another example of how our faculty not only teach but also prepare students to be successful.”

 

TCNJ’s School of Nursing, Health, and Exercise Science educates aspiring health professionals to become future leaders across the healthcare industry. Faculty work closely with local healthcare partners to provide students with applicative skills and foundational knowledge. The nationally acclaimed school is dedicated to preparing individuals—through programs in nursing, public health, exercise science, and physical education teaching—for the many rewards of guiding people, communities, and populations toward improved health outcomes.